2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 401–500 of 2,029
Hsu, H., Kocis, P. T., Pichardo-Lowden, A. R., & Hwang, W. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13604 · Cited by 5
Wen, S., Li, Y., Xu, C., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s491897 · Cited by 5
Sorescu, T., Licker, M., Timar, R. Z., Muşuroi, C., Muntean, D., Voinescu, A., Vulcănescu, D. D., Cosnita, A., Musuroi, S. I., & Timar, B. (2024) · Medicina · doi:10.3390/medicina60111870 · Cited by 7
Current Challenges in Pancreas and Islet Transplantation: A Scoping Review
Altabas, V., & Bulum, T. (2024) · Biomedicines · doi:10.3390/biomedicines12122853 · Cited by 6
SCHNETZER, L., Leiherer, A., Festa, A., Mündlein, A., PLATTNER, T., Mayer, G. J., Saely, C. H., & Drexel, H. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14374 · Cited by 6
Okawa, Y., & Mitsuhashi, T. (2024) · Kidney and Dialysis · doi:10.3390/kidneydial4040020 · Cited by 5
Min, X., Zhou, Y., Qu, Y.-F., Liao, Z., Li, H., Cheng, J., Liang, L., Mo, H., Wu, Z., & Xiong, X. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02417-1 · Cited by 6
Wan, X., Wang, Y., Liu, Z., Liu, Z., Zhong, S., & Huang, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-86290-7 · Cited by 10
“…diagnosed 3+ months after AP onset, as defined by one or more of the following: ① Fasting blood glucose ≥ 7.0 mmol/L, ② 2-h postprandial blood glucose ≥ 11.1 mmol/L (200 mg/dL), ③ HbA1c ≥ 6.5%, ④ typical symptoms of diabetes together with random blood glucose levels ≥ 11.1 mmol/L (200 mg/dL) 4,11 .”
InfluentialSmith, J., Martin, A., Mundadan, J., Roberts, M., Roman, Y. M., Bravo‐Nuevo, A., & Daghigh, F. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01586-y · Cited by 6
Pan, Z., Chen, Q., Lin, H., Huang, W., Li, J., Meng, F., Zhong, Z., Liu, W., Li, Z., Qin, H., et al. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-04804-3 · Cited by 7
“The fasting plasma glucose (FPG) and 2-h plasma glucose value during a 75-g OGTT were used to assess glycemic sta - tus [31 ].”
Nishikage, S., Nakagawa, Y., Hirota, Y., Yoshimura, K., Ueda, M., Yamamoto, A., Takayoshi, T., Matsuoka, A., Takahashi, M., Takeda, A., et al. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.008 · Cited by 5
Yang, Z., Shi, X., Wang, S., Du, L., Zhang, X., Zhang, K., Zhang, Y., Ma, J., & Zheng, R. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70055 · Cited by 10
Xie, L., Yu, P., & Shen, X. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01710-y · Cited by 5
Taormina, V. M., Eisenhardt, S., Gilbert, M. P., Poynter, M. E., Kien, C. L., & Kraft, J. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02616-4 · Cited by 6
“Notably, the inclusion criteria required the condition of prediabetes, defined as a fasting blood glucose concentration of 100–125 mg/dL or a hemoglobin A1C of 5.7–6.4% [24].”
InfluentialHeng, C., Wang, Y., Jiang, H., Gu, H., Li, Z., Niu, M.-M., Zhang, M., & Li, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117892 · Cited by 5
Guerrero‐Pérez, F., Rojas, N. V., Sánchez, I., Munguía, L., Jiménez‐Múrcia, S., Artero, C., Sobrino, L., Lazzara, C., Monseny, R., Montserrat, M., et al. (2025) · Nutrients · doi:10.3390/nu17132114 · Cited by 7
“…comorbidities were as follows: T2D diagnosis was based on glycosylated hemoglobin ≥ 6.5%, two fasting plasma glucose measurements ≥ 126 mg/dL, plasma glucose ≥ 200 mg/dL post-OGTT, random plasma glucose ≥ 200 mg/dL with hyperglycemia symptoms, or current use of glucose-lowering medication [32].”
InfluentialLyu, L., Fan, Y., Vogt, J. K., Clos‐Garcia, M., Bonnefond, A., Pedersen, H. K., Dutta, A., Koivula, R. W., Sharma, S., Allin, K. H., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01508-7 · Cited by 5
“The ADA prediabetes criteria include fasting plasma glucose (100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L)); 2-h plasma glucose after an OGTT (140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L)); or HbA1c (5.7–6.4%, 39–47 mmol/mol) [19].”
InfluentialTeixeira, P. P., Xu, Y. Y., Aravkin, A. Y., Zheng, P., Force, L. M., Kocarnik, J., McLaughlin, S. B., Vos, T., Lenox, H., Hay, S. I., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-13045-9 · Cited by 6
“…variable, in millimoles per liter (mmol/L), so studies providing HbA1c or plasma glucose after 2 h-OGTT were converted to FPG using FPG/HbA1c or FPG/ OGTT as a conversion factor assuming both 6.5% HbA1c and 2 h plasma glucose of 11.1 mmol/L after OGTT as an equivalent to 7 mmol/L of FPG 165 .”
InfluentialDiabetes trends and determinants among Thai adults from 2004 to 2020
Aekplakorn, W., Chariyalertsak, S., Bumrerraj, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-17619-5 · Cited by 5
“…previously diagnosed with diabetes by health professionals, was taking glucose-lowering medication, or had fasting plasma glucose (FPG) ≥ 126 mg/dL 15 Diagnosed diabetes (or awareness) was defined as self-reporting as being diagnosed with diabetes by health professionals or reported using…”
Li, M., Zhang, H.-P., Cheng, Y., Sun, L., Chen, S., Duan, X., Xian, C., Wu, S., & Yin, H. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05112-w · Cited by 6
“Prediabetes was defined according to the 2024 ADA criteria as an FBG level of 5.6–6.9 mmol/L, with no use of hypoglycemic medications, based on data collected during the baseline examination (2006–2007) [26].”
InfluentialHow clinically relevant is statin-induced diabetes?
Gerstein, H. C., & Pigeyre, M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00059-7 · Cited by 7
Cheang, I., Zhu, X., Huang, J., Tse, Y., Li, H., Ren, Q. W., Wu, M., Chan, Y., Xu, X., Tse, H., et al. (2024) · Cancer · doi:10.1002/cncr.35322 · Cited by 6
“15 Excluding patients who had major cardiovascular events (MACEs) within 2 years, patients in the prediabetes group were further classified and analyzed based on their glycemic status 2 years after the index date, as follows (see Figure S1): (1)”
Ye, M., Yu, G., Han, F., & He, H. (2024) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296241271382 · Cited by 5
Wang, S., Zhou, X., Wang, X., Cheng, S., Li, X., Nan, J., & Min, J. Z. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116425 · Cited by 5
Burden of Diabetes Mellitus in the Medically Underserved Rio Grande Valley
Gaddis, J. M., Arellano, E., Pullido, K., Torres, T., Chau-Zanetti, D., Quailes, N., & Suárez, A. (2024) · Cureus · doi:10.7759/cureus.70088 · Cited by 8
Chen, H., Tan, Q., Lai, S., Mai, H., & Wang, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-78679-7 · Cited by 8
Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment
Sánchez-Baya, M., Bolufer, M., Vázquez, F., Alonso, N., Massó, E., Paúl, J., Coll-Brito, V., Taco, O., Antón-Pàmpols, P., Gelpi, R., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041048 · Cited by 6
“The oral glucose tolerance test is the preferred test to make a diagnosis of PTDM [38].”
Wentzel, A., Smith, W. T., van Vuren, E. J., Kruger, R., Breet, Y., Wonkam-Tingang, E., Hanchard, N. A., & Chung, S. T. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00845.2024 · Cited by 7
Papassotiriou, I., Spiliopoulou, S., Dragonas, D., Tsoutsoura, N., Korompoki, E., & Manios, E. D. (2025) · European Journal of Clinical Nutrition · doi:10.1038/s41430-025-01573-6 · Cited by 5
“Similarly, the relationship between obesity and TOD was examined using multiple linear regression models with BMI categories as the independent variables; CCA-IMT and ICA-IMT, LVM, LVMI, and eGFR as the dependent variables in each model; and age, sex, smoking, diabetes, and dyslipidemia as…”
Liu, Y., Yin, X., Guo, Y., Xu, J., Shao, R., & Kong, Y. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03525-z · Cited by 6
The Spectrum of Adrenal Lesions in a Tertiary Referral Center
Martin, S. C., Andrei, M., Voicu, B., Riță, M. A., Taralunga, A. A., Sîrbu, A. M., Cima, L., Stoian, I., Barbu, C. G., Calu, V., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12102214 · Cited by 4
Diabetic Mastopathy: A Monocentric Study to Explore This Uncommon Breast Disease
Mariano, L., Nicosia, L., Scolari, S., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14232749 · Cited by 4
Iwama, N., Yokoyama, M., Yamashita, H., Miyakoshi, K., Yasuhi, I., Kawasaki, M., Arata, N., SATO, S. T., Iimura, Y., Masako, W., et al. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.14411 · Cited by 5
Wang, Q., Yan, T., Ma, C., Teng, X., Shen, C., Wang, N., Yu, K., Chu, W., Zhou, Q., & Liu, Z. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s501632 · Cited by 4
“6 It should still be noted that regarding the relationship between blood glucose level and the mortality rate of K. pneumoniae infection, studies have shown that in patients with KLA, the glycemic control level is not related to the patient’s mortality rate.”
Ribero, V. A., Efthimiou, O., Alwan, H., Bauer, D. C., Henrard, S., Waeber, G., Marques-Vidal, P. M., Rodondi, N., Giovane, C. D., & Gencer, B. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf296 · Cited by 5
“…used diabetes medication, or (iii) met any of the following diagnostic criteria: HbA1c > 6.5%, fasting glucose ≥ 7 mmol/L or oral glucose tolerance test measurement ≥ 11 mmol/L. 22 The definition of diabetes in each of the included cohorts is presented in Supplementary material online, Table S2 .”
InfluentialZhou, Y., Zhang, J., Lei, D., Qin, Y., Chen, Q., Tang, N., Tang, F., Huang, S., Lu, P., Jiang, L., et al. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118365 · Cited by 4
Bilancio, G., Hamzeh, S., Vecchione, N., Russo, D., Iacuzzo, C., Apicella, L., Pietro, R. A. D., Vitale, P., Amicone, M., Pisani, A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061303 · Cited by 4
Davidsen, L., Cichosz, S. L., Knoph, C. S., Larsen, I. M., Stæhr, P., Vestergaard, P., Jensen, M. H., Hartmann, B., Holst, J. J., Drewes, A. M., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70080 · Cited by 4
Glycemia Risk Index: A New Metric to Rule Them All?
Díaz-Soto, G., Pérez-López, P., Fernández-Velasco, P., & Bahillo-Curieses, P. (2025) · Diabetology · doi:10.3390/diabetology6060049 · Cited by 4
“The pathophysiology of T1D is based on an autoimmune reaction that destroys pancreatic beta cells (responsible for insulin production), leading to a situation of insulinopenia, with a lifelong need for insulin administration [3].”
Zhao, W., Zheng, D., Shi, X., Xu, F., Chen, L., Liu, X., Jin, X., Guan, Q., & Xu, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1536292 · Cited by 5
“It is used as a gold standard for the diagnosis of prediabetes and diabetes together with Hemoglobin A1c (HbA1c) (10).”
Cui, Y., Xu, Z., Ding, L., Li, Y., Zhou, X., & Li, L. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1608655 · Cited by 5
Shewade, H. D., Ravichandran, P., Satish, S., Pradeep, S. K., Jeyashree, K., Mahajan, P. B., Shah, A. N., Kirubakaran, R., & Kumar, A. M. V. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328619 · Cited by 4
“If three or more cFBG values are available during treatment, considering conversion of mean cFBG during treatment to an estimated HbA1c during treatment [42,43] 7.”
Sirico, A., Vastarella, M. G., Ruggiero, E., & Cobellis, L. (2025) · Nutrients · doi:10.3390/nu17142356 · Cited by 8
“GDM is associated with several maternal and fetal complications, including preeclampsia, macrosomia, neonatal hypoglycemia, and the long-term development of type 2 diabetes mellitus (T2DM) for both mother and child [2].”
Low prolactin levels as a marker of gestational diabetes in late pregnancy
Scairati, R., Auriemma, R. S., Meglio, S. D., Mastantuoni, E., Graziadio, C., Vecchio, G. D., Legnante, A., McEvoy, R. P., Newman, C., Dunne, F., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112404 · Cited by 5
Cooper, Z., Johnson, L. C. M., Patel, S. A., Sosale, A., Tandon, N., Anjana, R. M., Poongothai, S., Sridhar, G. R., Mohan, V., Chwastiak, L., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09810-1 · Cited by 4
“HbA1c is a continuous variable with typical ranges from 6.5%−14% for those who have a diagnosis of diabetes 34 .”
InfluentialIntermittent fasting in the treatment of type 2 diabetes
Dyńka, D., Rodzeń, Ł., Rodzeń, M., Łojko, D., Deptuła, A., Grzywacz, Ż., Kraszewski, S., Bartoń, K., Martin, P., Deptuła, A. M., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1629154 · Cited by 11
“(50, 65).”
Different association of GDF15 and FGF21 with glycemic status and aging in the context of obesity
Salmón‐Gómez, L., Catalán, V., Ramírez, B., Aguas‐Ayesa, M., Rodríguez, A., Becerril, S., Baixauli, J., Gutiérrez-Medina, S., Mugueta, C., Colina, I., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01830-3 · Cited by 7
“Participants were newly diagnosed with altered glucose homeostasis either IGT or T2D, following the criteria of the American Diabetes Association [31] and, therefore, were not receiving anti-diabetic treatments at the time of sampling.”
Method comparison of diabetes mellitus associated autoantibodies in serum specimens
Lenard, A., Rapp, A., Busch, S., & Findeisen, P. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0137 · Cited by 4
Dey, B. K., Banerjee, S., Adhikary, P., Chowdhury, S., Roy, S., Roy, S. B., & Bhattacharjee, R. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02581-5 · Cited by 6
“Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance first detected during preg - nancy and does not meet the criteria for overt diabetes [1].”
Idebenone: Clinical Potential Beyond Neurological Diseases
Yi, B., Zeng, J., Li, J., Liu, K., Zhu, X., Chen, X., & Gao, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s515053 · Cited by 9
Kozak, K., & Zajkowska, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199402 · Cited by 7
“Considering the high morbidity and mortality associated with complications of poorly controlled type 2 diabetes, early diagnosis is critical to enable timely intervention and the risk of disease progression [35].”
Duarte², M. P., Martins, P., Leal, D. V., Nóbrega, O. D. T., Ribeiro, H. S., & Viana, J. L. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.09.023 · Cited by 5
León, J., Bermúdez-López, M., Valdivielso, J. M., Pamplona, R., Torres, G., Mauricio, D., Castro-Boqué, E., Fernández, E., Caixàs, A., Bueno, M., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1689960 · Cited by 5
Koskenniemi, J. J., Clasen, J. L., You, L., Parikh, H. M., Vehik, K., Yang, J., Uusitalo, U. M., Veijola, R., Haller, M. J., Ziegler, A. G., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1198 · Cited by 6
Köger, M., Winkler, C., Hummel, S., Weiß, A., Koutangni, T., Yates, M., Bonnemaire, M., Guenther, O., ZACCAI, J. H., & Ziegler, A. (2025) · Diabetes Care · doi:10.2337/dc25-1021 · Cited by 5
Kuusela, S., Koskenniemi, J. J., Valtanen, T., Pokka, T. M.-L., Härkönen, T., Ilonen, J., Lempainen, J., Kyrönniemi, A., Toppari, J., Knip, M., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06573-6 · Cited by 8
Fogagnolo, C., Ortiz, G. U., Travieso, S. G., Venturini, A. C. R., Abud, G. F., Silva, B. M., da Silva, A. S. R., & de Freitas, E. C. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00711-7 · Cited by 5
Sontag, I., Kschischo, M., Kaltheuner, M., Jander, L., Leubner, P., Adamczewski, H., Weber, D., Hasenburg, A., Adamek, H. E., GestDiab Group, et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02000-3 · Cited by 4
“…the diagnosis can be confirmed between week 24–28 of gestation by an oral glucose tolerance test (OGTT) and alternatively by HbA1c or fasting plasma glucose (FPG) [8] Women with risk factors are advised to test for GDM prior to the recommended time range of 24th-28th week of gestation [10, 11].”
Xie, X., Li, X., Li, H., Gao, Y., Zhao, F., & Chen, J. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1642358 · Cited by 7
Alghamdi, A., Alanazi, M. A., Bukhari, S. Q., Alsumaira, R. A., Alenzi, R. H., Aljuhani, A. S., Alharbi, S. S., & Alsheikh, M. A. A. (2025) · Metabolites · doi:10.3390/metabo15120766 · Cited by 4
“Type 2 diabetes mellitus (T2DM) was identified based on the American Diabetes Association (ADA) criteria, which defined as either a confirmed clinical diagnosis under active treatment or an HbA1c value of ≥ 6.5% obtained within three months of the DEXA scan [21,22].”
InfluentialZhang, Z., Liu, J., Kang, Y., Liu, Y., & Fu, P. (2025) · Kidney Diseases · doi:10.1159/000548711 · Cited by 4
Elizondo-Elizondo, M., González-Silva, A., de Oca, G. M., Tirado‐Sánchez, A., León, M. G. F.-D., Diaz-Molina, V. L., Acosta‐Altamirano, G., & Bonifáz, A. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2607353 · Cited by 5
The transition from preclinical to clinical obesity: the importance of a borderline stage
Maldonado-Arvizu, J. E., Rios-Verdugo, P. V., Díaz‐Villanueva, J. F., Chimal‐Vega, B., Vique‐Sánchez, J. L., & García‐González, V. (2026) · Clinical Science · doi:10.1042/cs20256728 · Cited by 6
Relationship Between the Severity of Coronary Artery Disease and Renal Function
Karayakalı, M., Kadi, H., Karaman, K., Çelik, A., Özbek, K., Damar, İ. H., Zorlu, Ç., Atmaca, H., Ömür, S. E., & Önalan, O. (2026) · Angiology · doi:10.1177/00033197261416667 · Cited by 4
da Silva, A. M. P., Cardoso, L. J. C., Batista, S., Gonçalves, O. R., Paranhos, T., Teixeira, I. P. S., Guimarães, P. D., Franco, B. E., Cal, H. D. S. R., Salles, J. E. N., et al. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109306 · Cited by 6
Dynamic Smoking Patterns and Risk of Parkinson Disease and All-Cause Mortality
Ahn, S., Kim, D. H., Park, J., Yoon, J., & Lee, J.-H. (2026) · Neurology · doi:10.1212/wnl.0000000000214651 · Cited by 4
Long, J., Zhao, J., Gu, X., & Huang, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1829579 · Cited by 6
Kawada, N., Kamachi, K., Tamura, M., Tamura, M., Kitamura, R., Susaki, K., Yamamoto, H., Kobayashi, H., Matsuoka, R., & Ishihara, O. (2024) · Foods · doi:10.3390/foods13162628 · Cited by 6
“A general consensus has not reached an ideal dietary balance for people with glucose intolerance [2,3]; however, some dietary patterns, foods, and nutrients, such as Mediterranean food, low glycemic index (GI) food, and dietary fiber reduce the risk of T2D [4–7].”
BackgroundKumar, J., & A, U. M. (2024) · Cureus · doi:10.7759/cureus.70462 · Cited by 4
“Patients were diagnosed with T2DM according to the American Diabetes Association criteria (glycated hemoglobin (HbA1C): ≥6.5% (48 mmol/mol), fasting blood sugar (FBS): ≥126 mg/dL (7.0 mmol/L)) [16].”
MethodInfluentialCacciatore, S., Martone, A. M., Ciciarello, F., Galluzzo, V., Gava, G., Massaro, C., Calvani, R., Tosato, M., Marzetti, E., Landi, F., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-79329-8 · Cited by 8
“To further evaluate the variation of WCR across the diabetes spectrum, individuals with a fasting blood glucose level between 100 and 125 mg/dL or a random blood glucose level between 140 and 199 mg/dL were classified as having pre-diabetes 31 .”
Statlender, L., Robinson, E., Grossman, A., Duskin-Bitan, H., Shochat, T., Itzhaki, M. H., Fishman, G., Singer, P., Kagan, I., & Bendavid, I. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.11.024 · Cited by 4
Shimodaira, M., Minemura, Y., & Nakayama, T. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00293-6 · Cited by 4
Identification of Adipsin as a Biomarker of Beta Cell Function in Patients with Type 2 Diabetes
Park, J., Nguyen, T. N., Shim, H. M., Yu, G. I., Ha, E. Y., & Cho, H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237351 · Cited by 4
“The criteria for selecting the T2D groups are as follows: (1) those who are satisfied with the diagnosis in accordance with the ADA guidelines [1] and (2) a person diagnosed with T2D or undergoing treatment with diabetes medication.”
Kongmalai, T., Tansawet, A., Pattanaprateep, O., Ratanatharathorn, C., Amornritvanich, P., Looareesuwan, P., Boonwatcharapai, B., Khunakorncharatphong, A., Nimitphong, H., Srinonprasert, V., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-090226 · Cited by 4
Hu, K., Zhao, X., Zhang, N., Ma, J., Zhang, R., Lu, Z., Wu, W., Ji, Y., & Li, X. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-024-02204-w · Cited by 5
Rivera-Valdes, J. J., Sifuentes-Franco, S., Ramírez-Meza, S. M., Íñiguez-Mosqueda, O., Morales‐Núñez, J. J., Ramírez-Evangelista, M. L., Reyes‐Pérez, I. V., & Graciano‐Machuca, O. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01575-y · Cited by 5
“…of the β-cells; type 2 (T2D), caused mainly by the progressive loss of insulin secretion by β-cells; gestational diabetes, a metabolic disorder diagnosed in the second or third trimester of pregnancy; and others types, such as genetic causes, exocrine pancreatic disorders, and medications[1].”
Ye, G., Zhang, Y., Peng, L., Yu, Z., Bai, Y., Wu, M., Lu, D., & Ding, C. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.02.028 · Cited by 4
Fiorentino, T. V., Vito, F. D., Natale, R. M., Sergi, S., Rubino, M., Cassano, V., Succurro, E., Sciacqua, A., Andreozzi, F., & Sesti, G. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112075 · Cited by 4
Gao, C., Liu, J., Wang, D., Liu, M., & Qiu, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-91787-2 · Cited by 7
“…for diabetes in non-pregnant individuals recommended by the American Diabetes Association, where two abnormal results were required to confirm the diagnosis in the absence of unequivocal hyperglycemia or classic diabetic symptoms; (3) regular use of antidiabetic medications, including insulin 7 .”
Regulatory T cell-based therapies for type 1 diabetes: a narrative review
Velikova, T. V., Vasilev, G., Linkwinstar, D., Siliogka, E., Kokudeva, M., Miteva, D., Vasilev, G., Gulinac, M., Atliev, K., & Shumnalieva, R. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.52 · Cited by 5
Ruggeri, R. M., Grossrubatscher, E. M., Ciocca, E., Hasballa, I., Jaafar, S., Oldani, M., Rubino, M., Russo, F., Isidori, A. M., Colao, A. A. L., et al. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09958-5 · Cited by 5
“The incidence of NETs has been steadily increasing over the last decades [1, 3], in parallel with the increasing prevalence and incidence of diabetes mellitus (DM) [4], and the two conditions strongly associate and influence each other [5–9].”
Wang, S., Ning, X., Tu, J., Wang, J., & Zhao, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1523787 · Cited by 9
Süygün, H., Yalçınkaya, D., & Karakulak, U. N. (2025) · Diagnostics · doi:10.3390/diagnostics15111372 · Cited by 4
“DM was defined as a fasting glucose > 126 mg/dL, HbA1c > 6.5% or a history of antidiabetic medications [26].”
InfluentialPalermi, S., Vecchiato, M., Brusiani, S., Martino, L. D., Luca, M. D., Fernando, F., Cavarretta, E., Niebauer, J., Volpe, M., & Biffi, A. (2025) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-025-00722-z · Cited by 4
“According to 2024 ADA guidelines [18] resting fasting glycemia ≥ 126 mg/dL suggests diabetes.”
Nurkolis, F., Syahputra, R. A., Nugrahanto, A. P., Taslim, N. A., Mustika, A., Tjandrawinata, R. R., Harbuwono, D. S., & Soegondo, S. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01762-0 · Cited by 7
Wang, W., Lin, F., Zhang, C., Chang, X., Wang, G., & Feng, L. (2025) · BMC Public Health · doi:10.1186/s12889-025-23675-3 · Cited by 5
“…5.7-6.4% or fasting plasma glucose (FPG) level of 5.6–6.9 mmol/L following diagnostic criteria out-lined by the American Diabetes Association (ADA) [19] which was also applied in the local clinical guideline for the prevention and treatment of type 2 diabetes mellitus and expert consensus [20, 21].”
InfluentialGrzych, G., Defauwes, I., de Tullio, P., Pekar, J. D., Brousseau, T., Lippi, G., & Cavalier, E. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2533855 · Cited by 4
“…of Laboratory Medicine (EFLM ) strongly recommend using venous plasma promptly separated within 30 min of collection, or collected into fluoride-citrate tubes when immediate centrifugation is not feasible, to ensure reliable glucose values and avoid spurious hypoglycemia due to glycolysis [22].”
Application of monoclonal antibodies in diabetes: A bibliometric analysis from 2004–2024
Wei, R., Jia, B., Zheng, S., Zhang, X., Wang, M., Sun, N., Zhang, R., & Li, Q. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2536910 · Cited by 4
Teixeira, L. C. R., Pereira, J. D., Mamede, I., Caramelli, P., Silva, V., Veloso, A., Luizon, M. R., & Gomes, K. B. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70196 · Cited by 6
“T2DM re-sults from the progressive dysfunction of pancreatic β-cells, alongside decreased sensitivity of peripheral tissues to insulin (Artasensi et al. 2020; Chatterjee et al. 2017; American Diabetes Association Professional Practice 2024).”
Chen, Z., Li, Y., & Zhu, X. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s528826 · Cited by 5
Chen, R., Guo, Q., Bai, C., Li, J., Chen, Y., Tan, J., Zhang, L., Fei, J., & Zhou, S. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01924-0 · Cited by 4
“1): age < 35 years, BMI < 25 kg/m², unintentional weight loss, ketoacidosis, or blood glucose > 360 mg/dL [30].”
BMDMs in metabolic memory impair fracture healing in diabetes
Zhang, D., Liu, C., Yuan, Y., Su, J., Wang, Z., Jian, C., & Yu, A. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04677-9 · Cited by 8
Zade, S. R., Khasbage, S. U., Mishra, A., & Mehani, R. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101442 · Cited by 9
Population Prevalence, Penetrance, and Mortality for Genetically Confirmed MODY
Sharp, L. N., Colclough, K., Leech, J. M., Cannon, S. J., Laver, T. W., Hattersley, A. T., Weedon, M. N., & Patel, K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf599 · Cited by 16
Liu, X., Wu, S., Yang, Y., Li, Y., Zhang, X., Liu, R., Qin, L., & Li, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1631647 · Cited by 4
“a. Patients diagnosed with type 2 diabetes(T2DM) following the criteria of the 2024 American Diabetes Association (34); b. Patients aged ≥ 18 years; c. Patients with complete indicators (triglyceride and fasting glucose).”
Alshadfan, H., Mirghani, H. O., Alrasheed, T., Alanazi, M. A., Alatawi, A. M., Elodemi, M., & Somchit, M. N. (2026) · Medicine · doi:10.1097/md.0000000000046320 · Cited by 4
“[5,6] The use of metformin is often hindered by gastrointestinal (GI) adverse effects.”
Lee, S. U., Hong, S., Choi, S. K., Kim, S. M., Shin, J. E., Kil, K., Kim, Y. H., Wie, J. H., Jo, Y. S., & Ko, H. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-57535-8 · Cited by 5
“The American Diabetes Association concluded that GDM diagnosis can be accomplished with either of the two strategies; however, there is still controversy regarding which method is better regarding long-term prognosis 5 .”
BackgroundThe effect of incretin-based drugs on the riks of acute pancreatitis: a review
Czaplicka, A., & Kaleta, B. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01430-6 · Cited by 4
Davison, N. B., Gaffney, C. J., Kerns, J. G., & Zhuang, Q. (2024) · Engineering Research Express · doi:10.1088/2631-8695/ad4aed · Cited by 3
Gupta, Y., Goyal, A., & Tandon, N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15722 · Cited by 4
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.